CD79A and autoimmune bullous skin disease: Given the evolution of this patient’s disseminated rash and its temporal relationship with the administration of meropenem with prior sensitization by isoniazid, we propose that the developed MDH with 2 distinct clinical presentations—DRESS in the setting of isoniazid and TEN-like linear IgA bullous dermatosis in the setting of repeated exposure to meropenem.